Development and Practical Application of a Library of CID Accurate Mass
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; a Web-Based Approach
ORIGINAL RESEARCH published: 09 February 2021 doi: 10.3389/fpsyt.2020.632405 Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach Valeria Catalani 1*, Davide Arillotta 1, John Martin Corkery 1, Amira Guirguis 1,2, Alessandro Vento 3,4,5 and Fabrizio Schifano 1 1 Psychopharmacology, Drug Misuse & Novel Psychoactive Substances Research Unit, School of Life & Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom, 2 Swansea University Medical School, Institute of Life Sciences 2, Swansea University, Swansea, United Kingdom, 3 Department of Mental Health, ASL Roma 2, Rome, Italy, 4 Addictions’ Observatory (ODDPSS), Rome, Italy, 5 Department of Psychology, Guglielmo Marconi University, Rome, Italy COVID-19-related disruptions of people and goods’ circulation can affect drug markets, especially for new psychoactive substances (NPSs). Drug shortages could cause a change in available NPS, with the introduction of new, unknown, substances. The aims of the current research were to use a web crawler, NPSfinder®, to identify and categorize emerging NPS discussed on a range of drug enthusiasts/psychonauts’ websites/fora at the time of the pandemic; social media for these identified NPS were screened as Edited by: well. The NPSfinder® was used here to automatically scan 24/7 a list of psychonaut Ornella Corazza, University of Hertfordshire, websites and NPS online resources. The NPSs identified in the time frame between United Kingdom January and August 2020 were searched in both the European Monitoring Center Reviewed by: for Drugs and Drug Addictions (EMCDDA)/United Nations Office on Drugs and Crime Simona Zaami, Sapienza University of Rome, Italy (UNODC) databases and on social media (Facebook, Twitter, Instagram, Pinterest, Laura Hondebrink, and YouTube) as well, with a content qualitative analysis having been carried out on University Medical Center reddit.com. -
XXI. Gtfch-Symposium Poster
Toxichem Krimtech 2019;86(2):145 XXI. GTFCh-Symposium Poster P01 Impact of the NpSG on the number of hospitalisations due to NPS use Michaela Sommer1, Sebastian Halter1, Verena Angerer3, Volker Auwärter1, Maren Hermanns- Clausen2 1 Institut für Rechtsmedizin, Universitätsklinikum, Freiburg 2 Zentrum für Kinder- und Jugendmedizin, Vergiftungs-Informations-Zentrale, Universitätsklinikum, Freiburg 3 Institut für Rechtsmedizin, Kantonsspital St. Gallen, St. Gallen, Schweiz Aims: New psychoactive substances (NPS) have become a lasting threat to public health for many years. To prevent the emergence and spread of NPS, a new German law, the ‘NpSG’ (act on NPS), took effect in November 2016. This study presents an overview of analytically confirmed NPS intoxications during a 4-year period. To demonstrate effects of the act, the results of two years before and after the introduc- tion of the law were compared. Methods: Within the scope of a prospective observational study blood and urine samples were collected from emergency patients with suspected NPS intoxication. Compre- hensive drug analyses were performed by LC-MS/MS analysis. Results and Discussion: In the period considered, 137 patients were included. SC intake was verified in 63 cases (70%) in the 2-year period before and in 27 cases (77%) after the law change, respectively. Designer stimulants or hallucinogenic drugs were tested positive in 11 cases (12%) in the first period and in 15 cases (31%) in the second period. Since February 2017, four different SCs (cumyl-PEGACLONE, 5F-MDMB-P7AICA, EG-018, 5F-cumyl-P7AICA) not covered by the NpSG were detected in six cases. In the first period the most prevalent SC in the samples was MDMB-CHMICA (21 cases). -
A Metabolomics Investigation Into the Effects of HIV Protease Inhibitors On
Molecular BioSystems View Article Online PAPER View Journal | View Issue A metabolomics investigation into the effects of HIV protease inhibitors on HPV16 E6 expressing Cite this: Mol. BioSyst., 2014, 10,398 cervical carcinoma cells† Dong-Hyun Kim,‡§a J. William Allwood,§¶a Rowan E. Moore,b Emma Marsden-Edwards,8b Warwick B. Dunn,¶a Yun Xu,a Lynne Hampson,c Ian N. Hampsonc and Royston Goodacre*ad Recently, it has been reported that anti-viral drugs, such as indinavir and lopinavir (originally targeted for HIV), also inhibit E6-mediated proteasomal degradation of mutant p53 in E6-transfected C33A cells. In order to understand more about the mode-of-action(s) of these drugs the metabolome of HPV16 E6 expressing cervical carcinoma cell lines was investigated using mass spectrometry (MS)-based metabolic profiling. The metabolite profiling of C33A parent and E6-transfected cells exposed to these two anti- viral drugs was performed by ultra performance liquid chromatography (UPLC)-MS and gas Creative Commons Attribution 3.0 Unported Licence. chromatography (GC)-time of flight (TOF)-MS. Using a combination of univariate and multivariate Received 23rd September 2013, analyses, these metabolic profiles were investigated for analytical and biological reproducibility and to Accepted 2nd January 2014 discover key metabolite differences elicited during anti-viral drug challenge. This approach revealed DOI: 10.1039/c3mb70423h both distinct and common effects of these two drugs on the metabolome of two different cell lines. Finally, intracellular drug levels were quantified, which suggested in the case of lopinavir that increased www.rsc.org/molecularbiosystems activity of membrane transporters may contribute to the drug sensitivity of HPV infected cells. -
Wo 2010/075090 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC. -
Respiratory Depression • • Loss of Consciousness Serotonergic Syndrome and • Constipation Nausea and Vomiting Convulsion
Opioids in daily practice Dr Frédéric Lebrun Soins intensifs et urgences pédiatriques Unité pédiatrique de prise en charge de la douleur, CHC-Liège Belgian Paediatric Pain Association Fear of morphine and opioids ! Opioid Crisis in the US Opioids restrictions Restricting the use of codeine in children and breastfeeding women (2013) Restricting the use of tramadol in children and breastfeeding women (2017) Adverse opioids reactions Serotonic effect : • Respiratory depression • • Loss of consciousness Serotonergic syndrome and • Constipation Nausea and vomiting convulsion • Dry mouth Chronic opioid abuse : • Drowsiness • Tolerance • Pruritus • Dependence • Withdrawal • Addiction Opioids in my daily practice ? Serious ADRs ADRs very unlikely when opioids are titrated carefully ! Awareness of the possible sides effects should not lead to underuse of opioids ! Good practice guidelines • Multimodal approach : Non-phramacological Pharmacological • Best suited treatment to patient situation • Favor oral route (moderate pain) • Give at regular interval • Prevent procedural pain • Quickly adapt therapy according to resudal pain • Monitor and prevent adverse drug reactions (ADRs) • Use protocols Which analgesic medication ? Type of pain Patient’s condition Intensity ? Age ? Route ? Cormorbidities ? Fast onset ? Co-adminstrations ? Duration ? Setting of care ? Past-experience? Mecanism ? Hospital ? Home ? Which analgesic medication ? • Paracétamol • Benzodiazépines • AINS • Spasmolytiques • Morphiniques • Clonidine • Dexmédétomidine • Kétamine • -
Club Drugs Wheel (Display Poster Version 1.0.4 • 30/08/2020)
Club Drugs Wheel (Display poster version 1.0.4 • 30/08/2020) eartbeat, sweating ng h , en aci well-bein erg R nce, g, eu y y fide pho Be ep Con ppetite, clen ria lo le ed a ched ng s y wer jaw Co in , tch Lo upils, paranoia s nn g e i d p , an S e , af , ng late xie e ct s hi Di ings, arousal, im ty xu io u rm at sw pote S al n, n , a re aty ood nc w a d e w b e M A e ea ro e e sw l R t, u s r a MP i e s fr p , w sk w s r , aine a t o ia a Heroin a - t r MDPV Khat o r l o a le s r d one f m , 4F-MPH t n o th Methadone o n i b h i Coc t e i , A d h r n d a s p w eh , e c il u , Bupr MDMA i i p n e e MD yd o c n n i p c v t g , Ethylphenidate r e i v u a n F enorphine Mephedr a l , e entanyl Amphetamine t r e , t n p e d PMMA i h i s o s n n Morphine Methamphetamine n e d d u e / a y y e e a p PMA, o n e t s n t n e Methylone v , d g d Dihydr ButyloneAPB e f d c , o u e fi n i r r g , h v n i r AI 5/6- o r n l t e ocodeine y e n Tr 2- c m g i s amadol Kr d r o e s t Ethylone, t 2-MPPP d i o atom 3-FPM AI r i y e n 5/6-MAPB o C d a o e r MD F o m O-desmethyltr Isotonitazene t s n e i C o one 4,4’-DMAR A o e v V edr 4-MT n O U-47700 2-methyl x S amadol L a Me APDI O p h 4-MPM 5- M o s -bucinnazine Nicotine V t Caeine p i t g s m e Diazepam o o r a e n Nortilidine I x] u c s i m i o 5-IA 2C[- o n e n t o t 2CI, i d c 2CE, i u e i d k T 2CB, t o emazepam n , d i a c m 5-MeO-DALT n f g n g o 1P-LSD g , a l e l Alcoho v , GHB, GBL l c s n a p 25[-x]-NBOMe d b i i o c e w o r 5-MeO-DIBF , d k xide m n diazepo 25[- o x]-NBOH o , i s Chlor o n a Poppers -
CREW NPS Booklet
NEW Psychoactive DRUGS V1.7 05/15 Service availability Drop-in: Monday – Wednesday: 1pm – 5pm, Thursday: 3pm – 7pm, Friday – Saturday: 1pm – 5pm, Sunday: Closed Telephone information and support: Monday – Friday: 10am – 5pm Online information and chatroom support: www.mycrew.org.uk Address | 32 Cockburn Street | Edinburgh | EH1 1PB Telephone | 0131 220 3404 Email | [email protected] Main | www.crew2000.org.uk Enterprise | www.mindaltering.co.uk Info and support | www.mycrew.org.uk Facebook | www.facebook.com/Crew2000 Twitter | www.twitter.com/Crew_2000 Instagram | www.instagram.com/Crew_2000 This booklet has been designed to expand worker knowledge and confidence in the area of NPS. It is most useful when discussed as part of Crew’s NPS training. Crew was established in 1992, in response to the rapid expansion of recreational drug use. We provide up-to-date information on the drugs that people are taking so they can make informed decisions about their own health. This is achieved using a stepped care approach and through collaboration with volunteers, service users and professionals. Crew neither condemns nor condones drug use, but we believe there are ways to reduce harm to health. As a national agency, Crew is at the forefront of emerging drug trends and we engage at all levels including service development, practice and policy. Our services include: – Support line: non-judgmental drug and sexual health information and support. – Drop-in: drug and sexual health information, condoms (NHS c:card service) and DJ workshops. – Outreach services: we provide welfare at large events, such as clubs and festivals to educate revellers on partying safely. -
(12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma Et Al
US 20100081713A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0081713 A1 Sharma et al. (43) Pub. Date: Apr. 1, 2010 (54) COMPOSITIONS AND METHODS FOR (22) Filed: Mar. 18, 2009 TREATINGVIRAL INFECTIONS Related U.S. Application Data (75) Inventors: Geeta Sharma, Singapore (SG); (60) Provisional application No. 61/069,917, filed on Mar. Ralf Altmeyer, Singapore (SG); 19, 2008. Vishal Pendharker, Singapore (SG); Yu Chen, Singapore (SG); Publication Classification Michael Foley, Chestnut Hill, MA (51) Int. Cl. (US) A63L/35 (2006.01) A6II 3L/25 (2006.01) Correspondence Address: A63L/35 (2006.01) Gearhart Law LLC A6II 3/13 (2006.01) 4 Femdale Avenue A6IP3L/2 (2006.01) Chatham, NJ 07928 (US) (52) U.S. Cl. .......... 514/459; 514/529; 514/647: 514/662 (73) Assignee: CombinatoRx, (Singapore) Pte. (57) ABSTRACT Ltd. The present invention provides compositions, methods, and kits for treating or preventing a viral infection (e.g., an infec (21) Appl. No.: 12/406,716 tion caused by an influenza virus). Patent Application Publication Apr. 1, 2010 Sheet 1 of 2 US 2010/0081713 A1 ------ 80 r -0. Vehicle 0.5% HPMC g - - Sertraline-30mg/kg/day - £ 60 “A Sertraline-100mg/kg/day/kg/day i -v. Oseltamivir-30mg/kg/day ...i -0. Oseltamivir-100mg/kg/day -0. (Sertraline 30mg/kg+ . 40 Prednisolone 0.1 mg/Kg) Figure 1 Patent Application Publication Apr. 1, 2010 Sheet 2 of 2 US 2010/0081713 A1 100 468OOO 2 O Wehicle Sentraline 10 mg/kg Sentraline 30mg/kg Setraline 100mg/kg Figure 2 US 2010/008 1713 A1 Apr. -
BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department -
(12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley Et Al
US 2014O144429A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0144429 A1 Wensley et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND DEVICES FOR COMPOUND (60) Provisional application No. 61/887,045, filed on Oct. DELIVERY 4, 2013, provisional application No. 61/831,992, filed on Jun. 6, 2013, provisional application No. 61/794, (71) Applicant: E-NICOTINE TECHNOLOGY, INC., 601, filed on Mar. 15, 2013, provisional application Draper, UT (US) No. 61/730,738, filed on Nov. 28, 2012. (72) Inventors: Martin Wensley, Los Gatos, CA (US); Publication Classification Michael Hufford, Chapel Hill, NC (US); Jeffrey Williams, Draper, UT (51) Int. Cl. (US); Peter Lloyd, Walnut Creek, CA A6M II/04 (2006.01) (US) (52) U.S. Cl. CPC ................................... A6M II/04 (2013.O1 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., ( ) Draper, UT (US) USPC ..................................................... 128/200.14 (21) Appl. No.: 14/168,338 (57) ABSTRACT 1-1. Provided herein are methods, devices, systems, and computer (22) Filed: Jan. 30, 2014 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (63) Continuation of application No. PCT/US 13/72426, an electronic nicotine delivery device and for Smoking or filed on Nov. 27, 2013. nicotine cessation. Patent Application Publication May 29, 2014 Sheet 1 of 26 US 2014/O144429 A1 FIG. 2A 204 -1 2O6 Patent Application Publication May 29, 2014 Sheet 2 of 26 US 2014/O144429 A1 Area liquid is vaporized Electrical Connection Agent O s 2. -
Analytical Reference Standards
Cerilliant Quality ISO GUIDE 34 ISO/IEC 17025 ISO 90 01:2 00 8 GM P/ GL P Analytical Reference Standards 2 011 Analytical Reference Standards 20 811 PALOMA DRIVE, SUITE A, ROUND ROCK, TEXAS 78665, USA 11 PHONE 800/848-7837 | 512/238-9974 | FAX 800/654-1458 | 512/238-9129 | www.cerilliant.com company overview about cerilliant Cerilliant is an ISO Guide 34 and ISO 17025 accredited company dedicated to producing and providing high quality Certified Reference Standards and Certified Spiking SolutionsTM. We serve a diverse group of customers including private and public laboratories, research institutes, instrument manufacturers and pharmaceutical concerns – organizations that require materials of the highest quality, whether they’re conducing clinical or forensic testing, environmental analysis, pharmaceutical research, or developing new testing equipment. But we do more than just conduct science on their behalf. We make science smarter. Our team of experts includes numerous PhDs and advance-degreed specialists in science, manufacturing, and quality control, all of whom have a passion for the work they do, thrive in our collaborative atmosphere which values innovative thinking, and approach each day committed to delivering products and service second to none. At Cerilliant, we believe good chemistry is more than just a process in the lab. It’s also about creating partnerships that anticipate the needs of our clients and provide the catalyst for their success. to place an order or for customer service WEBSITE: www.cerilliant.com E-MAIL: [email protected] PHONE (8 A.M.–5 P.M. CT): 800/848-7837 | 512/238-9974 FAX: 800/654-1458 | 512/238-9129 ADDRESS: 811 PALOMA DRIVE, SUITE A ROUND ROCK, TEXAS 78665, USA © 2010 Cerilliant Corporation. -
ATP, 489 Absolute Configuration Benzomotphans, 204 Levotphanol
Index AIDA, 495 Affinity labeling, analogs of (Cont.) cAMP, 409, 489 motphine,448 ATP, 409, 489 naltrexone, 449 [3H] ATP, 489 norlevotphanol,449 Absolute configuration normetazocine, 181 benzomotphans, 204 norpethidine, 232 levotphanol, 115 oripavine, 453 methadone and analogs, 316 oxymotphone, 449 motphine, 86 K-Agonists, 179,405,434 phenoperidine, 234 Aid in Interactive Drug Analysis, 495 piperazine derivatives, 399 [L-Ala2] dermotphin, 363 prodines and analogs, 272 [D-Ala, D-Leu] enkephalin (DADL), 68, 344 sinomenine, 28, 115 [D-Ala2 , Bugs] enkephalinamide, 347, 447 viminol, 400 [D-Ala2, Met'] enkephalinamide, 337, 346, Ac 61-91,360 371,489 Acetylcholine, 5, 407 [D-Ala2]leu-enkephalin, 344, 346, 348 Acetylcholine analogs, 186, 191 [D-Ala2] met-enkephalin, 348 l-Acetylcodeine, 32 [D-Ala2] enkephalins, 347 Acetylmethadols (a and (3) Alfentanil, 296 maintenance of addicts by a-isomer, 304, 309 (±)-I1(3-Alkylbenzomotphans, 167, 170 metabolism, 309 11(3-Alkylbenzomotphans, 204 N-allyl and N-CPM analogs, 310, 431 7-Alkylisomotphinans, 146 stereochemistry, 323 N-Alkylnorketobemidones, 431 synthesis, 309 N-Alkylnorpethidines, 233 X-ray crystallography, 327 N-Allylnormetazocine, 420 6-Acetylmotphine, receptor binding, 27 N-Allylnormotphine, 405 Acetylnormethadol, 323 N-Allylnorpethidine, 233 8(3-Acyldihydrocodeinones, 52 3-Allylprodines (a and (3), 256 14-Acyl-4,5-epoxymotphinans, 58 'H-NMR and stereochemistry, 256 7-Acylhydromotphones, 128 X-ray crystallography, 256 Addiction, 4 N-Allylnormetazocine, 420 Adenylate cyclase, 6, 409, 413, 424,